Skip to content

Useability and Acceptability of the CUE1 Device in Older People With Parkinson's Disease

Useability and Acceptability of the CUE1 Device in Older People With Parkinson's Disease

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06430151
Enrollment
20
Registered
2024-05-28
Start date
2024-05-16
Completion date
2024-12-16
Last updated
2024-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

The CUE1 device is a non-invasive wearable device for people with Parkinson's Disease (PD) approved for sale in the UK. The CUE1 device utilises two established methods to improve motor symptoms in PD, namely pulsed cueing and vibrotactile stimulation. Many people with PD wish to explore non-pharmacological interventions as an adjunct to manage their motor symptom. Study design and eligibility: This feasibility study is to establish whether the CUE1 device is a useable and acceptable device for older people with PD. 20-25 participants aged \>60 years with PD will be recruited from a movement disorder service to the study. Methodology: Participants will undertake baseline assessments of motor symptoms and quality of life with a PD nurse assessor in their own home. Following this the CUE1 device will be fitted and repeat assessments of motor symptoms will take place after 20 minutes. The participants will complete a daily diary of useability and acceptability for 4 weeks. A second visit will occur at 4 weeks with the same PD nurse assessor where the final set of motor symptom and quality of life assessments will be completed.

Interventions

DEVICECUE1

Sternal worn focused vibrotactile stimulation and cueing device

Sponsors

Dr Alistair Mackett
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Useability and acceptability study of a vibrotactile stimulation device

Eligibility

Sex/Gender
ALL
Age
60 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1\. Individuals under the care of a Cambridge University Hospitals Foundation Trust movement disorder service with an established clinical diagnosis of Parkinson's disease based on the UK Brain bank criteria

Exclusion criteria

1. Co-existing significant neurological disorder (disabling stroke, multiple sclerosis, dementia, motor neurone disease), 2. Atypical parkinsonian disorder diagnosis (e.g. multiple systems atrophy, progressive supranuclear palsy or cortical basal degeneration syndrome) 3. co-existing physical impairment or disability causing significant mobility impairment (severe lower limb osteoarthritis) 4. trauma or pain to the sternum 5. use of other medical device e.g. pacemaker, deep brain stimulator, TENS machine etc 6. lacking capacity to consent to the study 7. Sensitivity to medical adhesives 8. Existing participant in intervention research trial

Design outcomes

Primary

MeasureTime frameDescription
Useability and acceptability of the CUE1 device in older people with Parkinson's disease4 weeksParticipants' completion of a patient diary which will collect safety, tolerability, useability, and efficacy reports of the device over the study period. Participants will also complete a Patient Global Impression of Change (PGI-C) questionnaire at the end of the study.

Secondary

MeasureTime frameDescription
To undertake standardized, validated measurements of motor function with use of the CUE1 device4 weeksCompletion of validated motor scores during the study period to evaluate feasibility of the data collection method for motor symptom change. Any signals of improvement in motor scores would potentially justify larger randomised controlled studies to evaluate this systematically.

Countries

United Kingdom

Contacts

Primary ContactAlistair J Mackett, MBBS
alistair.mackett1@nhs.net01223 217483

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026